Drug Trial Radar · NCT07118449
Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABG
Last checked: Nov 19, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
116
Planned (sponsor's estimate)
Start
Aug 27, 2025
Primary completion
Dec 30, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- XyloCor Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 26-week (with a 26-week extension) multicenter, randomized, double-blind, placebo-controlled Phase 2 study of XC001 versus placebo. Approximately 116 participants who have CAD and have been referred for revascularization by CABG and who have, according to assessment by stress imaging multiple myocardial segments that are substantially ischemic, and that are unlikely to be fully revascularized during CABG for technical reasons, including diffuse atherosclerosis, lack of conduits, or insufficient target vessels. Patients will be randomized in a 1:1 to XC001 or placebo injections during the final stages of the CABG procedure. Patients will have a baseline CMR at day 4-6 post CABG and additional assessments in the primary study period will be performed on Day 14, and Weeks 4, 12, and 26, (and during the extension period at 52 weeks).
Conditions
- Coronary Artery Disease (CAD)
Interventions
XC001Drug
22 injections will be administered at the end of the CABG procedure as a one time treatment.
A195/placeboDrug
22 injections of A195/placebo will be administered at the end of the CABG procedure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline (Day 4-6 CMR) in treated segment(s) comparing XC001 and placebo in CMR imaging parameters at Weeks 12 and 26 post-surgery.Time frame: Week 26
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Christ Hospital
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.